Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3357603 | 0.89 | TLR7 (0.46) | TLR7TLR8 | |
| SCHEMBL3350927 | 0.86 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL8142637 | 0.86 | TLR7 (0.54) | TLR7TLR8 | |
| SCHEMBL13431445 | 0.85 | TLR7 (0.51) | TLR7TLR8 | |
| SCHEMBL3350498 | 0.85 | TLR7 (0.48) | TLR7TLR8 | |
| SCHEMBL3355143 | 0.83 | TLR7 (0.54) | TLR7TLR8 | |
| SCHEMBL14301420 | 0.83 | TLR7 (0.46) | TLR7TLR8 | |
| SCHEMBL26351757 | 0.82 | TLR7 (0.53) | TLR7TLR8 | |
| SCHEMBL18587108 | 0.82 | TLR7 (0.51) | TLR7TLR8 | |
| SCHEMBL3354252 | 0.82 | TLR7 (0.49) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | claimed |
| CN-115554406-A | anti-CD 20 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-115350279-A | anti-HER 2 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-115337402-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-115252792-A | anti-EGFR combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-114716555-A | Compounds and compositions for targeting EGFR expressing tumors | 博笛生物科技有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114671954-A | Compounds and compositions targeting HER2 positive tumors | 博笛生物科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-02-03 | — | — | US | claimed |
| US-20220016152-A1 | IMMUNE MODULATORY COMBINATIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-01-20 | — | — | US | claimed |
| CN-113633783-A | Compounds and compositions for immunotherapy | 博笛生物科技有限公司 | 2021-11-12 | — | — | CN | claimed |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2018-04-26 | — | — | US | claimed |
| EP-3298131-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | The Regents of The University of California (US) | 2018-03-28 | — | — | EP | claimed |
| US-9827329-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-11-28 | — | — | US | claimed |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-10-12 | — | — | US | claimed |
| US-20170114137-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2017-04-27 | — | — | US | claimed |
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-03-02 | — | — | US | claimed |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2017-02-02 | — | — | US | claimed |
| US-20160375148-A1 | Compounds and Compositions for Treating EGFR Expressing Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2016-12-29 | — | — | US | claimed |
| WO-2016187459-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-24 | — | — | WO | claimed |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-11-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114137-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | PDCD1LG2, CD274, PDCD1 | TLR7 879/4885TLR8 585/4885 |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885 |
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | TP53, MCL1, MSH2 | TLR7 1537/4885TLR8 2076/4885 |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | ERBB2, EGFR, TP53 | TLR7 362/4885TLR8 249/4885 |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TLR7 883/4885TLR8 671/4885 |
| US-20220016152-A1 | IMMUNE MODULATORY COMBINATIONS AND METHODS FOR TREATING CANCERS | CD47, IFNG, GZMB | TLR7 97/4885TLR8 84/4885 |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | CD47, TP53, CD74 | TLR7 198/4885TLR8 159/4885 |
| US-20160375148-A1 | Compounds and Compositions for Treating EGFR Expressing Tumors | EGFR, ERBB2, ERBB3 | TLR7 634/4885TLR8 518/4885 |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TLR7 980/4885TLR8 901/4885 |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.